BeOne Medicines

#News for #Investors and #Media:      We’re announcing a new collaboration with Revolution Medicines that leverages the strengths of our companies and shared purpose to advance innovation for patients with difficult-to-treat cancers around the world.      Read the full press release here: https://lnkd.in/dZSqabZ3

This summer, interns across the globe have been learning, collaborating, and contributing across BeOne.    Different teams. Different perspectives. One shared purpose. We caught up with four interns across Quality Assurance, HR, Patient Advocacy, and Communications to see what a day in the life looks like across our internship program.     By investing in the next generation of talent, we're helping build the future of healthcare for the patients and communities we serve. Thank you to our interns for bringing their curiosity and passion to our teams this summer.    Interested in learning more about what we do and the opportunities available at BeOne? https://lnkd.in/gQRaVchs     #TeamBeOne #Careers #ProfessionalDevelopment 

Every clinical trial begins with a patient. Congratulations to American Association for Cancer Research (AACR) on the first patient enrolled in the AACR-ADOPT-GEA trial, an important step forward in biomarker-driven research for gastroesophageal adenocarcinoma. Collaboration is essential to innovative science, and we’re fortunate to be working alongside organizations that share our commitment to oncology research and improving patient outcomes. #GastroesophagealCancer #CancerResearch

One quarter, many saves in motion ⚽ At BeOne, we know that progress in cancer does not happen in a single moment. It is built through many saves: the scientific decision that opens a new path, the clinical milestone that creates new possibility, the execution that helps innovative solutions reach more patients worldwide. Our Q2 2026 results show that momentum in action. Our five key takeaways: 𝟭. 𝗥𝗲𝘃𝗲𝗻𝘂𝗲 𝗿𝗲𝗮𝗰𝗵𝗲𝗱 $𝟭.𝟳𝗕 BeOne reported Q2 revenue of $1.7B, representing 30% growth from the prior-year period. 𝟮. 𝗡𝗲𝘁 𝗶𝗻𝗰𝗼𝗺𝗲 𝘁𝗼𝘁𝗮𝗹𝗲𝗱 $𝟮𝟯𝟳𝗠 Net income totaled $237M, with GAAP diluted earnings per ADS of $2.05. 𝟯. 𝗚𝗿𝗼𝘀𝘀 𝗺𝗮𝗿𝗴𝗶𝗻 𝗶𝗺𝗽𝗿𝗼𝘃𝗲𝗱 𝘁𝗼 𝟵𝟬% Gross margin increased to 90%, compared with 87% in the prior-year period. 𝟰. 𝗖𝗼𝗻𝘁𝗶𝗻𝘂𝗲𝗱 𝗰𝗼𝗺𝗺𝗲𝗿𝗰𝗶𝗮𝗹 𝗴𝗿𝗼𝘄𝘁𝗵 Highlights included 31% growth in global sales of our BTK inhibitor compared to the prior-year period, U.S. FDA accelerated approval of our BCL-2 inhibitor for adults with relapsed or refractory MCL, and Japan regulatory approval of our PD-1 inhibitor for adults with first-line gastric cancer. 𝟱. 𝗠𝗲𝗮𝗻𝗶𝗻𝗴𝗳𝘂𝗹 𝗽𝗶𝗽𝗲𝗹𝗶𝗻𝗲 𝗽𝗿𝗼𝗴𝗿𝗲𝘀𝘀 Our pipeline progress in Q2 included:   • Positive topline results from the Phase 3 study in treatment-naïve mantle cell lymphoma  • Continued advancement of our BTK degrader through potentially registrational Phase 2 studies  • On track progress in our Phase 3 trial against pirtobrutinib  • Five solid tumor programs achieving clinical proof of concept and advancing toward pivotal development  • Receiving FDA Orphan Drug Designation for our PRMT5 inhibitor in pancreatic ductal adenocarcinoma 𝗟𝗲𝗮𝗿𝗻 𝗺𝗼𝗿𝗲: https://lnkd.in/gbh9XRBq

#News for #Investors and #Media: BeOne Medicines announces second quarter 2026 financial results and business updates.  Read the full press release: https://lnkd.in/gcK9Swpv

#News for #Investors and #Media: We’re expanding our U.S. manufacturing footprint.    Today, we're announcing a $300 million expansion of our flagship U.S. manufacturing and clinical R&D facility at the Princeton West Innovation Campus in Hopewell, New Jersey.     The investment adds small molecule manufacturing capacity, brings our total U.S. manufacturing investment to more than $1 billion, creates 120 new jobs, and supports the advancement of our deep oncology pipeline of more than 35 clinical and commercial-stage assets.      This expansion strengthens BeOne's global manufacturing network, helping us deliver transformative cancer medicines to more patients in the U.S. and around the world. Together, we're how the world stops cancer.    🔗Read more: https://lnkd.in/da57uSsd   #BeOneInnovator #Oncology 

#News for #Investors and #Media: Our investigational PRMT5 inhibitor was granted Orphan Drug Designation by the FDA for the treatment of pancreatic cancer. Despite remarkable advances in cancer care, pancreatic cancer remains one of oncology's areas of greatest unmet need, reinforcing the importance of continued research and innovation. #PancreaticCancer #BeOneInnovator

Two nights ago, Switzerland proved their worth against Columbia to go on to qualify for the quarter finals at World Cup. After a gruelling 120 minutes, the country I call home, won their fight in an exciting penalty shoot out whereby Switzerland‘s goalie Gregor Kobel made a flying save that determined the outcome of the match. 🇨🇭 That save. Some moments on the pitch are impossible to look away from. In cancer care, saves look different - a diagnosis made earlier, a treatment that opened a door, a person who showed up. But the feeling? The same. One Save Changes Everything. #CancerHasNoBorders #WorldCup2026 #BeOneAgainstCancer

🩸Still have questions about using AI in blood cancer care? Join us on Wednesday, July 15 at 1 PM ET / 6 PM BST for our first Educational Forum Watch Party as we revisit one of our most popular sessions: Empowered by AI: Navigating Blood Cancer Care Through Technology with Lisa Porat and Anand Reddi. This engaging discussion explores how artificial intelligence can help patients, caregivers, healthcare providers, and advocates navigate the complexities of blood cancer care with greater confidence and empowerment. We're especially grateful to Lisa Porat, MSW, LCSW, FAOSW, BeOne Medicines Director of North America Patient Partnerships, and Anand Reddi, BeOne Medicines Global Head of Direct-to-Customer Innovation and Digital Health, for joining us live to answer additional questions in this new watch party format. 📺 Watch the session together 💬 Stay for a live Q&A ❓ Submit questions in advance: https://ow.ly/PVz850ZhlBH Register today: https://ow.ly/rjuj50ZhlBG #Waldenstrom #BloodCancer #ArtificialIntelligence #PatientEmpowerment #WMCommunity #IWMF #BeOneMedicines

#TeamBeOne was proud to turn awareness into action at this year's #FunRunMunich26. It was inspiring to join forces with Digestive Cancers Europe and run alongside patients, caregivers, and oncologists to raise awareness for digestive cancers and highlight the importance of healthy living. A big thank you to DiCE and #OutdoorAgainstCancer, as well as all those who walked and ran in the event, for championing this vital cause. Today was a meaningful reminder of the power of community as we unite to support patients and strive together to improve the lives of those impacted by cancer. #DigestiveCancers #ESMOGI26